Latest & greatest articles for osteoarthritis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoarthritis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoarthritis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoarthritis

541. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 2 of 2): economic results

drawn. Health technology The study examined viscosupplementation with hylan G-F 20 for the treatment of osteoarthritis (OA) of the knee in Canada. The comparator was treatment without hylan G-F 20 Type of intervention Treatment. Economic study type Cost-utility analysis. Study population The study population included ambulatory patients over 40 years old in Canada with a primary diagnosis of radiologically verified OA in the study knee (knee most symptomatic or with the most predominant (...) A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 2 of 2): economic results A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 2 of 2): economic results A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation

2002 NHS Economic Evaluation Database.

542. Therapeutic ultrasound for osteoarthritis of the knee. (Abstract)

abstracted by two reviewers (VW, LB), and checked by a third reviewer (BS) using a pre-developed adapted form for the OA sub-group of the Cochrane Musculoskeletal Group. The same two reviewers, using a validated scale, assessed the methodological quality of the RCTs and CCTs independently. OA outcome measures were extracted from the publications. The pooled analysis was performed using weighted mean differences (WMDs) for joint counts, pain, global and functional assessments. A chi-square test was used (...) galvanic current or short wave diathermy for the outcomes of pain and patient-assessed improvement.Ultrasound therapy appears to have no benefit over placebo or short wave diathermy for patients with knee OA. These conclusions are limited by the poor reporting of the characteristics of the device, of the population, of the OA,and therapeutic application of the ultrasound and low methodological quality of the trials included. No conclusions can be drawn about the use of ultrasound in smaller joints

2001 Cochrane

543. Glucosamine therapy for treating osteoarthritis. (Abstract)

Glucosamine therapy for treating osteoarthritis. Osteoarthritis (OA) is the most common form of arthritis, and it is often associated with significant disability and an impaired quality of life.To review all randomized controlled trials (RCTs) evaluating the effectiveness and toxicity of glucosamine in osteoarthritis (OA).We searched MEDLINE, Embase, and Current Contents up to November 1999, and the Cochrane Controlled Trials Register. We also wrote letters to content experts, and hand searched (...) reference lists of identified RCTs and pertinent review articles.Relevant studies met the following criteria: 1) RCTs evaluating the effectiveness and safety of glucosamine in OA, 2) Both placebo based and comparative studies were eligible, 3) Both single blinded and double-blinded studies were eligible.Data abstraction was performed independently by two investigators and the results were compared for degree of agreement. Gotzsche's method and a validated tool (Jadad 1995) were used to score the quality

2001 Cochrane

544. Herbal therapy for treating osteoarthritis. (Abstract)

Herbal therapy for treating osteoarthritis. The increasing popularity of complementary and alternative medicine appears to be particularly evident amongst people with chronic disease. In the treatment of osteoarthritis, one therapy that has been identified as having potential benefit, is herbal medicine (phytotherapy).To determine the effectiveness of herbal therapies in treating osteoarthritis.Databases for mainstream and complementary medicine were searched using terms to include all forms (...) of arthritis combined with herbal medicine. We searched the following electronic databases: MEDLINE, EMBASE, CISCOM, AMED, CINAHL, Cochrane Controlled Trials Register (CCTR), Cochrane Musculoskeletal specialized register, Dissertation Abstracts, BIDS ISI and the Cochrane Complementary Medicine Fields Specialized Register. We also searched the reference lists from retrieved trials.All randomized trials of herbal interventions in osteoarthritis, compared to placebo. Studies were included according

2001 Cochrane

545. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. (Abstract)

Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Treatment of osteoarthritis is usually limited to short-term symptom control. We assessed the effects of the specific drug glucosamine sulphate on the long-term progression of osteoarthritis joint structure changes and symptoms.We did a randomised, double-blind placebo controlled trial, in which 212 patients with knee osteoarthritis were randomly assigned 1500 mg sulphate (...) oral glucosamine or placebo once daily for 3 years. Weightbearing, anteroposterior radiographs of each knee in full extension were taken at enrolment and after 1 and 3 years. Mean joint-space width of the medial compartment of the tibiofemoral joint was assessed by digital image analysis, whereas minimum joint-space width--ie, at the narrowest point--was measured by visual inspection with a magnifying lens. Symptoms were scored by the Western Ontario and McMaster Universities (WOMAC) osteoarthritis

2001 Lancet Controlled trial quality: predicted high

546. The Oxford unicompartmental knee replacement for osteoarthritis

The Oxford unicompartmental knee replacement for osteoarthritis The Oxford unicompartmental knee replacement for osteoarthritis The Oxford unicompartmental knee replacement for osteoarthritis Brown A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Brown A. The Oxford unicompartmental knee replacement for osteoarthritis. Ottawa: Canadian (...) Coordinating Office for Health Technology Assessment/Office Canadien de Coordination de l'Evaluation des Technologies de la Sante (CCOHTA) 2001: 4 Authors' objectives To summarise the available evidence on the use of the Oxford unicompartmental knee replacement for osteoarthritis. Authors' conclusions The Oxford unicompartmental knee replacement is a reliable treatment for medial knee compartment osteoarthritis, provided patients with the correct indications are chosen and the appropriate surgical

2001 Health Technology Assessment (HTA) Database.

547. Pulsed signal therapy and the treatment of osteoarthritis

Modes d'Intervention en Sante. Pulsed signal therapy and the treatment of osteoarthritis. Montreal: Agence d'evaluation des technologies et des modes d'intervention en sante (AETMIS). AETMIS 01-2 RE. 2001 Authors' objectives The purpose of this report is to assess the efficacy of pulsed signal therapy (PST) in relieving pain and improving joint function in osteoarthritis. Authors' conclusions Osteoarthritis is a disease with a high prevalence, especially among the elderly. Having a noninvasive (...) conclusions can be drawn from the available scientific data, the latter strongly point to an analgesic effect and improved joint function in osteoarthritis. Furthermore, this technology cannot be considered purely experimental, since it is already being used by physiotherapy clinics, physicians in private practice and private individuals in Quebec and elsewhere in the world and since the user professionals consulted believe that pulsed electromagnetic field therapy may have a role to play

2001 Health Technology Assessment (HTA) Database.

548. Guidance on the use of cyclo-oxygenase (Cox) II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis

consideration of their risks and benefits, especially in patients who may be at increased risk of such adverse events. 1.3 Cox II selective inhibitors are not recommended for routine use in patients with rheumatoid arthritis (RA) or osteoarthritis (OA). They should be used, in preference to standard NSAIDs, when clearly indicated as part of the management of RA or OA only in patients who may be at high risk of developing serious gastrointestinal adverse effects. 1.4 Patients at high risk of developing (...) Guidance on the use of cyclo-oxygenase (Cox) II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis Guidance on the use of cyclo-oxygenase (Cox) II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis Guidance on the use of cyclo-oxygenase (Cox) II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis National Institute

2001 Health Technology Assessment (HTA) Database.

549. Hip resurfacing in younger people with osteoarthritis

Hip resurfacing in younger people with osteoarthritis Hip resurfacing in younger people with osteoarthritis Hip resurfacing in younger people with osteoarthritis Bisset A F Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Bisset A F. Hip resurfacing in younger people with osteoarthritis. London: Bazian Ltd (Editors), Wessex Institute for Health Research (...) and Development, University of Southampton 2001: 7 Authors' objectives This study aims to assess the effects of hip resurfacing for osteoarthritis in people under 65, compared with total hip replacement (THR). Authors' conclusions No evidence-based recommendations may be made from the research identified by our search. We found insufficient evidence about comparative efficacy of resurfacing versus replacement for this age group, although it could be argued that benefits and harms of THR are currently better

2001 Health Technology Assessment (HTA) Database.

550. Use of Hyaluronan in osteoarthritis of the knee (Sodium hyaluronate for intra-articular injection)

Use of Hyaluronan in osteoarthritis of the knee (Sodium hyaluronate for intra-articular injection) Use of Hyaluronan in osteoarthritis of the knee (Sodium hyaluronate for intra-articular injection) Use of Hyaluronan in osteoarthritis of the knee (Sodium hyaluronate for intra-articular injection) Medical Technology Unit - Swiss Federal Office of Public Health Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation Medical Technology Unit - Swiss Federal Office of Public Health. Use of Hyaluronan in osteoarthritis of the knee (Sodium hyaluronate for intra-articular injection) Medical Technology Unit - Swiss Federal Office of Public Health (MTU-SFOPH). 2001 Authors' objectives The aim of this report was to assess the statistical significance for the efficacy, tolerability and safety of Ostenil compared to Synvisc for the treatment

2001 Health Technology Assessment (HTA) Database.

551. Economic evaluation of nimesulide versus diclofenac in the treatment of osteoarthritis in France, Italy and Spain

for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of two drug therapies, nimesulide and diclofenac, for the treatment of osteoarthritis (OA). Both drugs are nonsteroidal anti-inflammatory drugs (NSAIDs), which although beneficial in reducing pain and inflammation, may result in potentially serious consequences in terms (...) Economic evaluation of nimesulide versus diclofenac in the treatment of osteoarthritis in France, Italy and Spain Economic evaluation of nimesulide versus diclofenac in the treatment of osteoarthritis in France, Italy and Spain Economic evaluation of nimesulide versus diclofenac in the treatment of osteoarthritis in France, Italy and Spain Tarricone R, Martelli E, Parazzini F, Darba J, Le Pen C, Rovira J Record Status This is a critical abstract of an economic evaluation that meets the criteria

2001 NHS Economic Evaluation Database.

552. Homeopathic remedies for the treatment of osteoarthritis: a systematic review

, BIOSIS Previews and the Cochrane Library. The search terms were: 'osteoarthritis', 'osteoarthrosis', 'degenerative joint disease', 'degenerative arthritis', 'degenerative arthrosis', 'gonarthrosis' and 'coxarthrosis'. The full text terms 'homeop*' and 'homoeop*' and the MeSH terms 'homeopathy' and 'alternative medicine' were also used. Additional published and unpublished material was identified by examining the bibliographies of located studies, reviews and the authors' own files, and by contacting (...) Homeopathic remedies for the treatment of osteoarthritis: a systematic review Homeopathic remedies for the treatment of osteoarthritis: a systematic review Homeopathic remedies for the treatment of osteoarthritis: a systematic review Long L, Ernst E Authors' objectives To locate and assess all randomised controlled trials (RCTs) of homeopathy in the treatment of patients with osteoarthritis (OA). Searching The databases searched from their inception to August 2000 included MEDLINE, EMBASE, AMED

2001 DARE.

553. Safety profile of nonprescription ibuprofen in the elderly osteoarthritis patient: a meta-analysis

Safety profile of nonprescription ibuprofen in the elderly osteoarthritis patient: a meta-analysis Safety profile of nonprescription ibuprofen in the elderly osteoarthritis patient: a meta-analysis Safety profile of nonprescription ibuprofen in the elderly osteoarthritis patient: a meta-analysis Ashraf E, Cooper S, Kellstein D, Jayawardena S Authors' objectives To assess the incidence of adverse experiences among elderly people taking multiple doses of non-prescription ibuprofen (...) for osteoarthritis pain, compared with placebo. Searching MEDLINE, EMBASE, BIOSIS Previews, International Pharmaceutical Abstracts, SciSearch, TOXLINE, CA SEARCH: Chemical Abstracts were searched. The dates and search terms were not reported. A textbook published in 1999 was also consulted. Study selection Study designs of evaluations included in the review Randomised trials (RCTs) that were double-blind and had a parallel-group design (not crossover) were eligible for inclusion. Specific interventions included

2001 DARE.

554. Herbal medicines for the treatment of osteoarthritis: a systematic review

Previews, CINAHL and the Cochrane Library were searched from their inception to May 2000. The search terms used were 'osteoarthritis', 'osteoarthrosis', 'degenerative joint disease', 'degenerative arthritis', 'degenerative arthrosis', 'gonarthrosis', 'coxarthrosis', 'botanic', 'phyto', 'herb', and all derivatives, together with individual plant and herb names. The bibliographies of the retrieved studies and reviews, and the authors' own files were also examined. Experts and manufacturers were contacted (...) Herbal medicines for the treatment of osteoarthritis: a systematic review Herbal medicines for the treatment of osteoarthritis: a systematic review Herbal medicines for the treatment of osteoarthritis: a systematic review Long L, Soeken K, Ernst E Authors' objectives To systematically review all randomised controlled trials (RCTs) on the effectiveness of herbal medicines and plant extracts, which are either taken orally or applied topically, for osteoarthritis. Searching MEDLINE, EMBASE, BIOSIS

2001 DARE.

555. Economic evaluation of aquatic exercise for persons with osteoarthritis

by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of aquatic exercise was compared with usual care for patients with osteoarthritis. Type of intervention Secondary prevention. Economic study type Cost-utility analysis. Study population The study population comprised patients with osteoarthritis. The site of the osteoarthritis, in terms of the affected joint, was not defined. The participants were eligible for inclusion if they met (...) the following criteria: there was a clinically confirmed diagnosis of osteoarthritis from a physician; they were aged 55 to 75 years; they were not currently exercising, defined as engaging in an average of less than 60 minutes exercise per week during the last month; they had permission from their primary physician to participate in the aquatic class; they were not currently enrolled in another medical study; they were not scheduled for joint replacement during the study; they were living in an area where

2001 NHS Economic Evaluation Database.

556. Health economic comparisons of rofecoxib versus conventional nonsteroidal antiinflammatory drugs for osteoarthritis in the United Kingdom

Health economic comparisons of rofecoxib versus conventional nonsteroidal antiinflammatory drugs for osteoarthritis in the United Kingdom Health economic comparisons of rofecoxib versus conventional nonsteroidal antiinflammatory drugs for osteoarthritis in the United Kingdom Health economic comparisons of rofecoxib versus conventional nonsteroidal antiinflammatory drugs for osteoarthritis in the United Kingdom Moore R A, Phillips C J, Pellissier J M, Kong S X Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health technology under investigation was rofecoxib, a new drug for the treatment of patients suffering from osteoarthritis. It is a selective COX-2 inhibitor and represents one of the two drugs in the "Coxibs

2001 NHS Economic Evaluation Database.

557. Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective

A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health intervention examined in the study was rofecoxib (24.7 mg daily) for the treatment of patients with osteoarthritis (OA). Type of intervention Treatment. Economic study type (...) Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective Marshall J K, Pellissier J M, Attard C L, Kong S X, Marentette M

2001 NHS Economic Evaluation Database.

558. Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis

evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of rofecoxib versus nonselective non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment of osteoarthritis (OA). Three daily dosages of rofecoxib could be administered, 12.5, 25 or 50 mg (the average daily dose was 24.7 mg (...) Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis Pellissier J M, Straus W L, Watson D J, Kon S X, Harper S E Record Status This is a critical abstract of an economic

2001 NHS Economic Evaluation Database.

559. Transcutaneous electrical nerve stimulation for knee osteoarthritis. Full Text available with Trip Pro

Transcutaneous electrical nerve stimulation for knee osteoarthritis. Osteoarthritis (OA) is a disease that affects synovial joints, which mainly causes degeneration and destruction of hyaline cartilage. To date, no curative treatment for OA exists. The primary goals for OA therapy are to relieve pain, maintain or improve functional status, and minimize deformity. Transcutaneous electrical nerve stimulation (TENS) is a noninvasive modality in physiotherapy that is commonly used to control both (...) acute and chronic pain arising from several conditions. A number of trials evaluating the efficacy of TENS in OA have been published.To assess the effectiveness of TENS in the treatment of knee OA. The primary outcomes of interest were those described by the Outcome Measures in Rheumatology Clinical Trials (OMERACT) 3, which included pain relief, functional status, patient global assessment, and change in joint imaging for studies of one year or longer. The secondary objective was to determine

2000 Cochrane

560. Non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the knee. (Abstract)

Non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the knee. To determine whether there is a difference in the relative efficacy of individual non-steroidal anti-inflammatory drugs (NSAIDs) when used in the management of osteoarthritis (OA) of the knee.We searched Medline (1966-1995) and Bids Embase (Jan-Dec, 1980-1995). The searches were limited to publications in the English language, and were last perfomed in November 1996. We used modified Cochrane Collaboration search (...) strategy to identify all randomised controlled trials. The MeSH heading osteoarthritis was combined with the generic names of the 17 non-aspirin NSAIDs licensed in the UK for the management of OA in general practice. The search of Embase used the term "osteoarthritis" if present in the abstract, title or keywords, and was combined with the generic names of the 17 non-aspirin NSAIDs, only if they were mentioned in the title, abstract or keywords.All double blind, randomised controlled trials

2000 Cochrane